Regulation FD Disclosure (Form 8-K)

Item 7.01 Regulation FD Disclosure.

On March 30, 2026, Protara Therapeutics, Inc. (the "Company" or "Protara") announced that the Company has received confirmation on the six-month complete response ("CR") rate of the 25^th Bacillus Calmette-Guérin ("BCG")-Unresponsive patient in its ongoing Phase 2 open-label ADVANCED-2 trial of TARA-002 in patients with carcinoma in situ or CIS (± Ta/T1) non-muscle invasive bladder cancer ("NMIBC"). The average six-month CR rate in the 25 BCG-Unresponsive patients is 68.0%, which is consistent with the 68.2% CR rate at six months that was announced by the Company on February 24, 2026, and is meaningfully above 41.9%.

As a result, the Company has determined that it has satisfied the condition set forth in its common stock purchase warrants issued in April 2024 (the "April 2024 Common Warrants") for fixing the termination date for exercise of the April 2024 Common Warrants. Specifically, the April 2024 Common Warrants are exercisable at an exercise price of $5.25 per share and may be exercised at any time on or prior to June 29, 2026.

The information contained in Item 7.01 of this Current Report on Form 8-K is being furnished and shall not be deemed to be "filed" for the purposes of Section 18 of the Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section and shall not be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.